Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol  a preliminary study

Coronel, Francisco; Cigarrán, Secundino; Gomis, Antonio Giner; Rodríguez-Cubillo, Beatriz; Herrero, José Antonio; Delgado, Pablo; Delgado, Jesús

doi:10.5414/cn107570

Cited by 12 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have previously investigated the protective effect of vitamin D on peritoneal membranes. Coronel et al reported a preliminary study showing that paricalcitol decreased peritoneal membrane permeability, with diminished peritoneal protein loss and increased ultrafiltration in PD patients [ 23 ]. Lee et al proved that calcitriol could decrease peritoneal fibrosis in a rat model of acute CG exposure.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells

Lee

Hung

Liou

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

Background. Peritoneal dialysis (PD) can induce fibrosis and functional alterations in PD patients' peritoneal membranes, due to long-term unphysiological dialysate exposure, partially occurring via triggering of epithelial-to-mesenchymal transition (EMT) in peritoneal mesothelial cells (MCs). Vitamin D can ameliorate these negative effects; however, the mechanism remains unexplored. Therefore, we investigated its possible links to MCs EMT inhibition. Methods. Peritoneal fibrosis was established in Sprague-Dawley rats by chlorhexidine gluconate (CG) intraperitoneal injection for 21 days, with and without 1α,25(OH)2D3 treatment. Morphological and functional evaluation and western blot analysis of EMT marker were performed upon peritoneum tissue. In vitro study was also performed in a primary human peritoneal MC culture system; MCs were incubated with transforming growth factor-β1 (TGF-β1) in the absence or presence of 1α,25(OH)2D3. EMT marker expression, migration activities, and cytoskeleton redistribution of MCs were determined. Results. 1α,25(OH)2D3 ameliorated CG-induced morphological and functional deterioration in animal model, along with CG-induced upregulation of α-SMA and downregulation of E-cadherin expression. Meanwhile, 1α,25(OH)2D3 also ameliorated TGF-β1-induced decrease in E-cadherin expression, increase in Snai1 and α-SMA expression, intracellular F-actin redistribution, and migration activity in vitro. Conclusion. 1α,25(OH)2D3 can ameliorate CG-induced peritoneal fibrosis and attenuate functional deterioration through inhibiting MC EMT.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recently, several studies have proven a protective effect of vitamin D against peritoneal fibrosis [ 23 – 27 ]. Furthermore, studies in the field of cancer research also found that vitamin D can ameliorate cancer cell EMT through the promotion of E-cadherin expression [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells

Lee

Hung

Liou

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In a prospective study, which included 23 patients on PD medicated with paricalcitol, with a mean dose of 1.3 µg/day and a follow-up period of 3 ± 2 months (range 2–5), Coronel et al [15] reported a decrease in PPL from 0.91 ± 0.35 to 0.76 ± 0.26 g/L (15.4%; p = 0.007) and from 7.55 to 6.46 g/24 h ( p < 0.033). In the control group, which included 15 patients not receiving any form of vitamin D, no changes in peritoneal membrane permeability were found.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to the usefulness in the treatment of hyperparathyroidism, the VDR activators have shown anti-inflammatory pleiotropic effects [11], antifibrotic properties [12] and inhibitory actions upon the renin angiotensin aldosterone system (RAAS) [13], demonstrating antiproteinuric action in patients with CKD [14]. The role of VDR activators in reduction of PPL has recently been a subject of interest; however, the results are controversial [15, 16]. The aim of this study was to analyze the relationship between therapy with paricalcitol and PPL in a cohort of PD patients.…”

Section: Introductionmentioning

confidence: 99%

Paricalcitol and Peritoneal Protein Loss in Peritoneal Dialysis: A Double-Center Study

et al. 2018

View full text Add to dashboard Cite

Background/Aims: Peritoneal protein loss (PPL) is associated with cardiovascular disease and mortality in peritoneal dialysis (PD). Controversial results have been published about the effect of paricalcitol in PPL among PD patients. This study intends to analyze the relationship between paricalcitol and PPL in PD. Methods: In a retrospective study, prevalent PD patients were divided into 2 groups: “with paricalcitol” and “without paricalcitol”. X²-test, Student’s t test, Pearson correlation coefficient and Logistic Regression analysis were applied. Results: Eighty-two patients were included. PPL was lower among patients medicated with paricalcitol (5.17 ± 1.71 vs. 6.79 ± 2.10 g/24 h, p = 0.0001). In multivariate analysis, paricalcitol and dialysate/plasma ratio of creatinine (D/P creatinine) were independently related to PPL (OR 4.270 [1.437–12.684], p = 0.009 and OR 0.205 [0.064–0.659], p = 0.008, respectively), adjusted for diabetes. Conclusion: Paricalcitol and D/P creatinine were independently related to PPL. Paricalcitol may have an effect on PPL in PD patients

show abstract

“…Interestingly, paricalcitol was associated with lower risk of hospitalization in those patients with more severe LVH [83]. Of note, paricalcitol resulted associated with significant reduction of oxidative stress [84] and improved peritoneal membrane permeability in hemodialysis and peritoneal dialysis, respectively [85]. However, no RCTs have tested the effect of paricalcitol against other forms of vitamin D on albuminuria and LVH.…”

Section: Vdra: a Multifaceted Choice From Secondary Hyperparathyromentioning

confidence: 99%

Which Vitamin D in CKD-MBD? The Time of Burning Questions

Galassi

Bellasi

Auricchio

et al. 2013

BioMed Research International

View full text Add to dashboard Cite

Vitamin D is a common treatment against secondary hyperparathyroidism in renal patients. However, the rationale for the prescription of vitamin D sterols in chronic kidney disease (CKD) is rapidly increasing due to the coexistence of growing expectancies close to unsatisfactory evidences, such as (1) the lack of randomized controlled trials (RCTs) proving the superiority of any vitamin D sterol against placebo on patients centered outcomes, (2) the scanty clinical data on head to head comparisons between the multiple vitamin D sterols currently available, (3) the absence of RCTs confirming the crescent expectations on nutritional vitamin D pleiotropic effects even in CKD patients, (4) the promising effects of vitamin D receptors activators (VDRA) against proteinuria and myocardial hypertrophy in diabetic CKD cohorts, and (5) the conflicting data on the impact on mortality of VDRA versus calcimimetic centered regimens to control CKD-MBD. The present review arguments these issues focusing on the opened questions that nephrologists should consider dealing with the prescription of nutritional vitamin D or VDRA and with the choice of a VDRA versus a calcimimetic based regimen in CKD-MBD patients.

show abstract

Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol a preliminary study

Cited by 12 publications

References 0 publications

Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells

Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells

Paricalcitol and Peritoneal Protein Loss in Peritoneal Dialysis: A Double-Center Study

Which Vitamin D in CKD-MBD? The Time of Burning Questions

Contact Info

Product

Resources

About

Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol  a preliminary study

Cited by 12 publications

References 0 publications

Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells

Vitamin D Can Ameliorate Chlorhexidine Gluconate-Induced Peritoneal Fibrosis and Functional Deterioration through the Inhibition of Epithelial-to-Mesenchymal Transition of Mesothelial Cells

Paricalcitol and Peritoneal Protein Loss in Peritoneal Dialysis: A Double-Center Study

Which Vitamin D in CKD-MBD? The Time of Burning Questions

Contact Info

Product

Resources

About

Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol a preliminary study